Trial Profile
Pharmacokinetics, Pharmacodynamics, and Safety of a Human Anti-IL-6 Monoclonal Antibody (Sirukumab) in Healthy Subjects in a First-in-Human Study.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Apr 2011
Price :
$35
*
At a glance
- Drugs Sirukumab (Primary)
- Indications Lupus nephritis; Rheumatoid arthritis
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- 07 Apr 2011 New trial record